The combination of SGLT2 and RAAS inhibition appeared to reduce the risk of the composite renal outcome, cardiovascular death, incident or worsening nephropathy and acute renal failure, but these results were based on single studies. The gene discussed is SLC5A2; the disease is kidney disorder.